Eli Lilly (NYSE:LLY) Raises FY23 Revenue Guidance To $33.4B-$33.9B From Prior Guidance Of $31.2B-$31.7B Vs. Consensus Of $31.44B; Sees Adjusted EPS Of $9.70-$9.90 From Prior Guidance Of $8.65-$8.85 Vs. Consensus Of $8.71
Eli Lilly (NYSE:LLY) Raises FY23 Revenue Guidance To $33.4B-$33.9B From Prior Guidance Of $31.2B-$31.7B Vs. Consensus Of $31.44B; Sees Adjusted EPS Of $9.70-$9.90 From Prior Guidance Of $8.65-$8.85 Vs. Consensus Of $8.71